ECRM_1170x120_8-1-17

National Pharmaceutical ­Council

Value-based contracts provide promise and potential

Value-based contracts provide promise and potential

There has been significant focus and attention paid to the issue of drug prices in the last few years. As Adam Fein, president of Pembroke Consulting Inc. and chief executive officer of Drug Channels Institute, has said, “Drugs are 12% of the costs, but 90% of the ­conversation.” Fortunately, the spirited national conversation about drug

Preserving the impact of biopharmaceutical innovation

Preserving the impact of biopharmaceutical innovation

NEW YORK — Health care economists, health system leaders and policy makers have been talking seriously about measuring and paying for value in health care for more than a decade. Hospitals, clinics, pharmacies and practitioners across the country now are starting to move in that direction, incentivized since 2015 by Medicare’s adoption of alternative care

Health care stakeholders need to talk

Health care stakeholders need to talk

With the heated rhetoric about Obamacare on the presidential campaign trail, congressional hearings focused on drug costs and news reports about these debates, is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and appropriate treatments and encourage future innovation? We believe

Access to medications, adherence go hand in hand

Access to medications, adherence go hand in hand

If the lack of medication adherence were an easy problem to solve, then everyone would be taking their medicines as directed, there would be no need for iPhone apps or electronic pill bottle reminders, patient health outcomes would be improved, and overall health care costs would be lower because of reduced complications or ­hospitalizations. Yet